Emerging drug targets for antiretroviral therapy

Drugs

Volumn 65, Issue 13, 2005, Pages 1747-1766

  Reeves, Jacqueline D ^a   Piefer, Andrew J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 3 O (3,3 DIMETHYLSUCCINYL)BETULIC ACID; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMD 070; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; APLAVIROC; CD4 IMMUNOGLOBULIN G2; CHEMOKINE; CMPD 167; CYANOVIRIN N; DEXTRAN SULFATE; ENFUVIRTIDE; HEPARIN; INDINAVIR; L 870812; MARAVIROC; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NAPHTHALENE SULFONATE; PRO 2000; PROTEINASE INHIBITOR; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ANTIGEN BINDING; CELL SURFACE; CLINICAL TRIAL; DISEASE COURSE; DNA INTEGRATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENZYME SUBSTRATE; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INJECTION SITE REACTION; LEUKOCYTOSIS; LIFE CYCLE; NONHUMAN; QT PROLONGATION; REVIEW; SIDE EFFECT; SOMATIC CELL GENETICS; VIRION; VIRUS ENVELOPE; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; ATTACHMENT SITES, MICROBIOLOGICAL; CARRIER PROTEINS; CELL ADHESION; CYTOSINE DEAMINASE; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV-1; INTEGRASES; MEMBRANE FUSION; PEPTIDE HYDROLASES; RECEPTORS, HIV; VIRAL ENVELOPE PROTEINS;

EID: 24344496912     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565130-00002     Document Type: Review

References (222)

1. UNAIDS. 2004 Report on the global AIDS epidemic: executive summary. Geneva: UNAIDS, 2004: 1-21
2. Sharma PL, Nurpeisov V, Hernandez-Santiago B, et al. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem 2004; 4 (9): 895-919
3. Ruane PJ, DeJesus E. New nucleoside/nucleotide backbone options: a review of recent studies. J Acquir Immune Defic Syndr 2004; 37: S21-9
4. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 2004; 4 (9): 921-44
5. Rodriguez-Barrios F, Gago F. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls. Curr Top Med Chem 2004; 4 (9): 991-1007
6. Wynn GH, Zapor MJ, Smith BH, et al. Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics 2004; 45 (3): 262-70
7. Gulick RM, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003; 17 (16): 2345-9
8. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004; 18 (5): 775-9
9. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337 (11): 725-33
10. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337 (11): 734-9
11. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853-60
12. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infectbility ed persons in 10 US cities. J Infect Dis 2004; 189 (12): 2174-80
13. Hammer SM, Pedneault L. Antiretroviral resistance testing comes of age. Antivir Ther 2000; 5 (1): 23-6
14. Wegner SA, Brodine SK, Mascola JR, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 2000; 14 (8): 1009-15
15. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347 (6): 385-94
16. Greenberg M, Cammack N, Salgo M, et al. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 2004; 14 (5): 321-37
17. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A 2003; 100 (19): 10598-602
18. De Clercq E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int J Biochem Cell Biol 2004; 36 (9): 1800-22
19. Dayam R, Neamati N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr Pharm Des 2003; 9 (22): 1789-802
20. Tomkowicz B, Collman RG. HIV-1 entry inhibitors: closing the front door. Expert Opin Ther Targets 2004; 8 (2): 65-78
21. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004; 10 (3): 315-36
22. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1 (1): 25-34
23. Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004; 14 (4): 255-70
24. Doms RW, Moore JP. HIV-1 membrane fusion: targets of opportunity. J Cell Biol 2000; 151 (2): F9-14
25. Doms RW. Chemokine receptors and HIV entry. AIDS 2001; 15 Suppl. 1: S34-5
26. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: another look. Trends Microbiol 1999; 7 (4): 144-9
27. Baribaud F, Pohlmann S, Doms RW. The role of DC-SIGN and DC-SIGNR in HIV and SIV attachment, infection, and transmission. Virology 2001; 286 (1): 1-6
28. Reeves JD, Doms RW. The role of chemokine receptors in HIV infection of host cells. In: Bradshaw RA, Dennis EA, editors. Handbook of cell signaling. New York: Academic Press, 2003: 191-6
29. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700
30. Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89 (2): 263-73
31. Weissenhorn W, Dessen A, Harrison SC, et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387 (6631): 426-30
32. Melikyan GB, Markosyan RM, Hemmati H, et al. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151 (2): 413-23
33. Kuhmann SE, Platt EJ, Kozak SL, et al. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 2000; 74 (15): 7005-15
34. Labrosse B, Labernardiere JL, Dam E, et al. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 2003; 77 (2): 1610-3
35. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002; 99 (25): 16249-54
36. Reeves JD, Miamidian JL, Biscone MJ, et al. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 2004; 78 (10): 5476-85
37. Reeves JD, Lee FH, Miamidian JL, et al. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79 (8): 4991-9
38. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74 (18): 8358-67
39. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75 (18): 8605-14
40. Parkin NT, Hellmann NS, Whitcomb JM, et al. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48 (2): 437-43
41. Callahan LN, Phelan M, Mallinson M, et al. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol 1991; 65 (3): 1543-50
42. Moulard M, Lortat-Jacob H, Mondor I, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74 (4): 1948-60
43. Esser MT, Mori T, Mondor I, et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 1999; 73 (5): 4360-71
44. Botos I, O'Keefe BR, Shenoy SR, et al. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. J Biol Chem 2002; 277 (37): 34336-42
45. Dey B, Lerner DL, Lusso P, et al. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 2000; 74 (10): 4562-9
46. Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41 (7): 1521-30
47. Turpin JA. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs 2002; 11 (8): 1077-97
48. Dumonceaux J, Nisole S, Chanel C, et al. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 1998; 72 (1): 512-9
49. Kolchinsky P, Mirzabekov T, Farzan M, et al. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999; 73 (10): 8120-6
50. LaBranche CC, Hoffman TL, Romano J, et al. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol 1999; 73 (12): 10310-9
51. Endres MJ, Clapham PR, Marsh M, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87 (4): 745-56
52. Reeves JD, McKnight A, Potempa S, et al. CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology 1997; 231 (1): 130-4
53. Bhattacharya J, Peters PJ, Clapham PR. CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS 2003; 17 Suppl. 4: S35-43
54. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol 2002; 83 (Pt 6): 1253-65
55. Reeves JD, Hibbitts S, Simmons G, et al. Primary human immuimmunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 1999; 73 (9): 7795-804
56. Edwards TG, Hoffman TL, Baribaud F, et al. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 2001; 75 (11): 5230-9
57. Hoffman TL, LaBranche CC, Zhang W, et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A 1999; 96 (11): 6359-64
58. Vermeire K, Bell TW, Choi HJ, et al. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharmacol 2003; 63 (1): 203-10
59. Vermeire K, Zhang Y, Princen K, et al. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002; 302 (2): 342-53
60. Vermeire K, Schols D. Specific CD4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003; 74 (5): 667-75
61. Vermeire K, Schols D, Bell TW. CD4 down-modulating compounds with potent anti-HIV activity. Curr Pharm Des 2004; 10 (15): 1795-803
62. Rusconi S, Moonis M, Merrill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996; 40 (1): 234-6
63. Reimann KA, Lin W, Bixler S, et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997; 13 (11): 933-43
64. Burkly LC, Olson D, Shapiro R, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody: dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992; 149 (5): 1779-87
65. Moore JP, Sattentau QJ, Klasse PJ, et al. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992; 66 (8): 4784-93
66. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189 (2): 286-91
67. Allaway GP, Davis-Bruno KL, Beaudry GA, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11 (5): 533-9
68. Trkola A, Pomales AB, Yuan H, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995; 69 (11): 6609-17
69. Jacobson JM, Israel RJ, Lowy I, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004; 48 (2): 423-9
70. Jacobson JM, Lowy I, Fletcher CV, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000; 182 (1): 326-9
71. Shearer WT, Israel RJ, Starr S, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis 2000; 182 (6): 1774-9
72. Guo Q, Ho HT, Dicker I, et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003; 77 (19): 10528-36
73. Lin PF, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A 2003; 100 (19): 11013-8
74. Madani N, Perdigoto AL, Srinivasan K, et al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol 2004; 78 (7): 3742-52
75. Si Z, Madani N, Cox JM, et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A 2004; 101 (14): 5036-41
76. McKnight A, Weiss RA. Blocking the docking of HIV-1. Proc Natl Acad Sci U S A 2003; 100 (19): 10581-2
77. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2 (11): 1240-3
78. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382 (6593): 722-5
79. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86 (3): 367-77
80. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273 (5283): 1856-62
81. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997; 185 (4): 621-8
82. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191 (6): 866-72
83. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272 (5263): 872-7
84. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73
85. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85 (7): 1149-58
86. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272 (5270): 1955-8
87. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384: 184-7
88. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381 (6584): 661-6
89. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85 (7): 1135-48
90. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384: 179-83
91. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270 (5243): 1811-5
92. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2 (4): 412-7
93. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382 (6594): 829-33
94. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382 (6594): 833-5
95. Mack M, Luckow B, Nelson PJ, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998; 187 (8): 1215-24
96. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276 (5310): 276-9
97. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004; 17 (1): 7-16
98. Kazmierski W, Bifulco N, Yang H, et al. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem 2003; 11 (13): 2663-76
99. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999; 96 (10): 5698-703
100. Dragic T, Trkola A, Thompson DA, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A 2000; 97 (10): 5639-44
101. Tsamis F, Gavrilov S, Kajumo F, et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003; 77 (9): 5201-8
102. Strizki JM, Xu S, Wagner NE, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98 (22): 12718-23
103. Tremblay CL, Giguel F, Kollmann C, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002; 46 (5): 1336-9
104. Reynes J, Rouzie R, Kanouni T, et al. SCH C: safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects [abstract]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
105. Schurmann D, Rouzier R, Nougarede R, et al. Antiviral activity of a CCR5 receptor antagonist [abstract no. 140LB]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)
106. Tagat JR, McCombie SW, Nazareno D, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors: IV. Discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1 (R)-4-(trifluoromethyl)phenyl]ethyl-3 (S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004; 47 (10): 2405-8
107. Maeda K, Nakata H, Koh Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004; 78 (16): 8654-62
108. Lalezari J, Thompson M, Kumar P, et al. 873140, a novel CCR5 antagonist: antiviral activity and safety during short-term monotherapy in HIV-infected adults [abstract no. 114]. 44th ICAAC; 2004 Oct 30-Nov 2; Washington, DC
109. Dorr P, Macartney M, Rickett G, et al. UK-427,857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5 [abstract no. 12]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston (MA)
110. Westby M, Smith-Burchnell C, Mori J, et al. In vitro escape of R5 primary isolates from the CCR5 antagonist, UK-427,857, is difficult and involves continued use of the CCR5 receptor [abstract]. Antivir Ther 2004; 9 (4): S10
111. Pozniak AL, Fatkenheuer G, Johnson M, et al. Effect of short term monotherapy with UK-427,857 on viral load in HIV-infected patients [abstract no. H-443]. 43rd Interscience Conference on Antiviral Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL)
112. Mosier DE, Picchio GR, Gulizia RJ, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73 (5): 3544-50
113. Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78 (6): 2790-807
114. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not inimplication volve CXCR4 use. Proc Natl Acad Sci U S A 2002; 99 (1): 395-400
115. Wolinsky SM, Veazey RS, Kunstman KJ, et al. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 2004; 328 (1): 19-29
116. Westby M, Whitcomb J, Huang W, et al. Predominance of CXCR4 utilising variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857 [abstract no. 538]. 11th Conference on Retroviruses and Opportunistic Intion fections; 2004 Feb 8-11; San Francisco (CA)
117. Schols D. HIV co-receptors as targets for antiviral therapy. Curr Top Med Chem 2004; 4 (9): 883-93
118. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393 (6685): 591-4
119. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393 (6685): 595-9
120. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2 (7): 581-7
121. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and elective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38 (4): 668-74
122. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4 (1): 72-7
123. Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186 (8): 1383-8
124. Schols D, Este JA, Henson G, et al. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/ CXCR-4. Antiviral Res 1997; 35 (3): 147-56
125. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCRantagonist: 4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44 (6): 1667-73
126. Schols D, Claes S, De Clercq E, et al. AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans [abstract no. 2]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
127. Fransen S, Huang W, Toma J, et al. Suppression of X4- and dual-tropic HIV-1 variants during a short course of monotherapy with the CXCR4 antagonist AMD 3100 [abstract]. Antivir Ther 2004; 9: S11
128. Schols D, Claes S, Hatse S, et al. Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist H [abstract no. 563]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston (MA)
129. Stone N, Dunaway S, Flexner C, et al. Biologic activity of an orally bioavailable CXCR4 antagonist in human subjects [abstract no. TuPeB4475]. XV International AIDS Conference; 2004 Jul 11-16; Bangkok
130. Miralles D. Needle-free administration of enfuvirtide with Biojector™ 2000 (B2000) demonstrates pharmacokinetic bioequivalence to standard needle administration. HIV, DART: Frontiers in Drug Development for AntiRetroviral Therapies; 2004 Dec 12-16; Montego Bay
131. Chen CH, Matthews TJ, McDanal CB, et al. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: inimplication for viral fusion. J Virol 1995; 69 (6): 3771-7
132. He Y, Vassell R, Zaitseva M, et al. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003; 77 (3): 1666-71
133. Gallo SA, Puri A, Blumenthal R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry 2001; 40 (41): 12231-6
134. Yuan W, Craig S, Si Z, et al. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol 2004; 78 (10): 5448-57
135. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348 (22): 2175-85
136. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348 (22): 2186-95
137. Miller MD, Hazuda DJ. HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resist Updat 2004; 7 (2): 89-95
138. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004 Aug; 54 (2): 333-40
139. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998; 72 (2): 986-93
140. Xu L, Pozniak A, Wildfire A, et al. Evolution of HR1 and HR2 mutations in HIV-1 gp41 associated with long-term enfuviragainst tide therapy [abstract no. 659]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)
141. Baldwin CE, Sanders RW, Deng Y, et al. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004; 78 (22): 12428-37
142. Poveda E, Rodes B, Toro C, et al. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 2002; 16 (14): 1959-61
143. Menzo S, Castagna A, Monachetti A, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48 (9): 3253-9
144. Lu J, Sista P, Giguel F, et al. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004; 78 (9): 4628-37
145. Marcelin AG, Reynes J, Yerly S, et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 2004; 18 (9): 1340-2
146. Greenberg ML, Davison D, Jin L, et al. In vitro antiviral activity of T-1249 a second generation fusion inhibitor [abstract]. Antivir Ther 2002; 7 Suppl. 1: S10
147. Miralles GD, Lalezari JP, Bellos N, et al. T-1249 demonstrates potent antiviral activity over 10 day dosing in most patients who have failed a regimen containing enfuvirtide (ENF): planned interim analysis of T1249-102, a phase I/II study [abstract no. 14lb]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston (MA)
148. Tremblay CL, Kollmann C, Giguel F, et al. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000; 25 (2): 99-102
149. Nagashima KA, Thompson DA, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183 (7): 1121-5
150. Eron JJ, Gulick RM, Bartlett JA, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 2004; 189 (6): 1075-83
151. Root MJ, Steger HK. HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 2004; 10 (15): 1805-25
152. Moore JP, Shattock RJ. Preventing HIV-1 sexual transmission: not sexy enough science, or no benefit to the bottom line? J Antimicrob Chemother 2003; 52 (6): 890-2
153. Shattock R, Solomon S. Microbicides: aids to safer sex. Lancet 2004; 363 (9414): 1002-3
154. Davis CW, Doms RW. HIV transmission: closing all the doors. J Exp Med 2004; 199 (8): 1037-40
155. Hu Q, Frank I, Williams V, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199 (8): 1065-75
156. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003; 19 (7): 535-41
157. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004; 20 (1): 11-8
158. Weber J, Nunn A, O'Connor T, et al. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV (89.6PD) in vitro and in vivo. AIDS 2001; 15 (12): 1563-8
159. Van Damme L, Wright A, Depraetere K, et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect 2000; 76 (2): 126-30
160. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003; 17 (3): 321-9
161. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306 (5695): 485-7
162. Veazey RS, Klasse PJ, Ketas TJ, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003; 198 (10): 1551-62
163. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266 (5187): 1024-7
164. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9 (3): 343-6
165. Haren L, Ton-Hoang B, Chandler M. Integrating DNA: transposases and retroviral integrases. Annu Rev Microbiol 1999; 53: 245-81
166. Condra JH, Miller MD, Hazuda DJ, et al. Potential new therapies for the
167. Daniel R, Greger JG, Katz RA, et al. Evidence that stable retroviral transduction and cell survival following DNA integration depend on components of the nonhomologous end joining repair pathway. J Virol 2004; 78 (16): 8573-81
168. Li L, Olvera JM, Yoder KE, et al. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J 2001; 20 (12): 3272-81
169. Farnet CM, Haseltine WA. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 1991; 65 (4): 1910-5
170. Bowerman B, Brown PO, Bishop JM, et al. A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev 1989; 3 (4): 469-78
171. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997; 71 (7): 5382-90
172. Farnet CM, Bushman FD. HIV-1 cDNA integration: requirement of HMG I (Y) protein for function of preintegration complexes in vitro. Cell 1997; 88 (4): 483-92
173. Lin CW, Engelman A. The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. J Virol 2003; 77 (8): 5030-6
174. Hindmarsh P, Ridky T, Reeves R, et al. HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro. J Virol 1999; 73 (4): 2994-3003
175. Chen H, Engelman A. The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc Natl Acad Sci U S A 1998; 95 (26): 15270-4
176. Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A 2002; 99 (10): 6661-6
177. Hazuda DJ, Anthony NJ, Gomez RP, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A 2004; 101 (31): 11233-8
178. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004; 305 (5683): 528-32
179. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287 (5453): 646-50
180. Kanamoto T, Kashiwada Y, Kanbara K, et al. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 2001; 45 (4): 1225-30
181. Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 2003; 100 (23): 13555-60
182. Zhou J, Chen CH, Aiken C. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3′,3′-dimethylsuccinyl}-betulinic acid. Retrovirology 2004; 1 (1): 15
183. Liang C, Hu J, Russell RS, et al. Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. J Virol 2002; 76 (22): 11729-37
184. Stoye JP. Fv1, the mouse retrovirus resistance gene. Rev Sci Tech 1998; 17 (1): 269-77
185. Kozak CA, Chakraborti A. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 1996; 225 (2): 300-5
186. Towers G, Bock M, Martin S, et al. A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A 2000; 97 (22): 12295-9
187. Best S, Le Tissier P, Towers G, et al. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 1996; 382 (6594): 826-9
188. Bieniasz PD. Restriction factors: a defense against retroviral infection. Trends Microbiol 2003; 11 (6): 286-91
189. Cowan S, Hatziioannou T, Cunningham T, et al. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A 2002; 99 (18): 11914-9
190. Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 2002; 99 (18): 11920-5
191. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic homobody component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427 (6977): 848-53
192. Goff SP. HIV: replication trimmed back. Nature 2004; 427 (6977): 791-3
193. Hatziioannou T, Perez-Caballero D, Yang A, et al. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A 2004; 101 (29): 10774-9
194. Yap MW, Nisole S, Lynch C, et al. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 2004; 101 (29): 10786-91
195. Keckesova Z, Ylinen LM, Towers GJ. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A 2004; 101 (29): 10780-5
196. Fisher AG, Ensoli B, Ivanoff L, et al. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987; 237 (4817): 888-93
197. Strebel K, Daugherty D, Clouse K, et al. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987; 328 (6132): 728-30
198. von Schwedler U, Song J, Aiken C, et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993; 67 (8): 4945-55
199. Gabuzda DH, Lawrence K, Langhoff E, et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 1992; 66 (11): 6489-95
200. Simon JH, Gaddis NC, Fouchier RA, et al. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 1998; 4 (12): 1397-400
201. Sheehy AM, Gaddis NC, Choi JD, et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418 (6898): 646-50
202. Luo K, Liu B, Xiao Z, et al. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 2004; 78 (21): 11841-52
203. Schafer A, Bogerd HP, Cullen BR. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004; 328 (2): 163-8
204. Zhang H, Yang B, Pomerantz RJ, et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424 (6944): 94-8
205. Mangeat B, Turelli P, Caron G, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424 (6944): 99-103
206. Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113 (6): 803-9
207. Lecossier D, Bouchonnet F, Clavel F, et al. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003; 300 (5622): 1112
208. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9 (11): 1404-7
209. Yu X, Yu Y, Liu B, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302 (5647): 1056-60
210. Garrus JE, von Schwedler UK, Pornillos OW, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001; 107 (1): 55-65
211. VerPlank L, Bouamr F, LaGrassa TJ, et al. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55 (Gag). Proc Natl Acad Sci U S A 2001; 98 (14): 7724-9
212. von Schwedler UK, Stuchell M, Muller B, et al. The protein network of HIV budding. Cell 2003; 114 (6): 701-13
213. Stuchell MD, Garrus JE, Muller B, et al. The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding. J Biol Chem 2004; 279 (34): 36059-71
214. Strack B, Calistri A, Craig S, et al. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003; 114 (6): 689-99
215. Martin-Serrano J, Yarovoy A, Perez-Caballero D, et al. Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci U S A 2003; 100 (21): 12414-9
216. Schubert U, Ott DE, Chertova EN, et al. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A 2000; 97 (24): 13057-62
217. Ott DE, Coren LV, Copeland TD, et al. Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus. J Virol 1998; 72 (4): 2962-8
218. Goff A, Ehrlich LS, Cohen SN, et al. Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release. J Virol 2003; 77 (17): 9173-82
219. Gottlinger HG, Dorfman T, Cohen EA, et al. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci U S A 1993; 90 (15): 7381-5
220. Sakai H, Tokunaga K, Kawamura M, et al. Function of human immunodeficiency virus type 1 Vpu protein in various cell types. J Gen Virol 1995; 76 (Pt 11): 2717-22
221. Geraghty RJ, Talbot KJ, Callahan M, et al. Cell type-dependence for Vpu function. J Med Primatol 1994; 23 (2-3): 146-50
222. Varthakavi V, Smith RM, Bour SP, et al. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 2003; 100 (25):15154-9